Contracts › 75N95023F00005
75N95023F00005: Standard and High Dose Ed Buprenorphine Induction. 09/15/2023 - 05/31/2026. N01DA-22-2253. Task Order 75N95023F00005 (TO9).
Awarded to The Emmes Company, Llc by National Institutes of Health (NIH).
$1.2Mobligated
$1.2Mpotential value
31 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N95023F00005 |
|---|---|
| Vehicle | 75N95022D00017 |
| Awardee | The Emmes Company, Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Period of performance | 15 September 2023 to 31 January 2027 |
| Potential end | 31 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record